Clinical trial NCT06511011: Chinese Medicine in Treating Insomnia
Official title: Efficacy and Safety of Modified Suan ZaoRen Tang-TianWang BuXin Dan in the Treatment of Chronic Insomnia: A Randomized, Double-blinded, Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Insomnia Chronic
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2024-07-19
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) at week 6.

Detailed description: Insomnia is one of the most general health concerns in the society. It is generally defined as a self-reported sleep disorder problem of the patient, characterized by difficulty in falling asleep, or difficulty maintaining sleep. According to American Insomnia Survey, 42.6% of the respondents reported of having at least one of the insomnia symptoms.

Chinese medicine can be an alternative to the treatment of insomnia. Suan Zao Ren Tang and Tian Wang Bu Xin Dan are two of the most common Chinese herbal formulae to treat insomnia, for which Suan Zao Ren Tang has the functions to nourish blood and calm the mind, clear heat and alleviate vexation, and Tian Wang Bu Xin Dan has the function to nourish the heart and calm the mind, and nourish Yin and clear heat. In this study, we will modify the formula of Suan ZaoRen Tang with TianWang BuXin Dan, and observe the effectiveness and safety of the study drug.

Eligibility criteria: Inclusion Criteria:

* Age from 18 to 65 years;
* Eligible for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for insomnia disorder. The criteria include having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 nights per week for at least 6 months;
* Insomnia Severity Index (ISI) total score of at least 8 indicating insomnia at the clinical level;
* Diagnosed to be Yin deficiency-induced internal heat pattern according to traditional Chinese Medicine (TCM) theory;
* Able to complete questionnaires and take medications as scheduled; and
* Voluntary written consent.

Exclusion Criteria:

* Known nervous system disease (eg, stroke, Parkinson's Disease);
* Known mental disorders (eg, depression or anxiety) or HADS score 11 or above in any either item;
* Known sleeping related diseases (eg. sleep apnea, nocturnal myoclonus, restless legs, severe nocturnal enuresis or narcolepsy) that may affect the sleeping quality;
* Known pharmacologically induced insomnia;
* With symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturition, and cough;
* Know treatment to comorbid sleep disorders, such as sleep apnea or narcolepsy;
* Work on shift or on night shift;
* Concomitant pharmacological treatment or herbal medicines for insomnia within the past month;
* Known severe medical conditions, such as cardiovascular, liver, kidney or hematopoietic system disease, diabetes mellitus, cancers, cerebrovascular diseases;
* Impaired hematological profile and liver / renal function exceeds the upper limit of the reference value by 2 times;
* Known alcohol and / or drug abuse;
* Known allergic history to any Chinese herbal medicines;
* Diagnosed to be deficiency of spleen according to TCM theory;
* Any contraindications for taking Chinese medicines in the opinion of the investigators;
* Know pregnant or lactating; and
* Involved in other interventional clinical studies at the same time.

Primary outcomes:
measure: The change in Pittsburgh Sleep Quality Index (PSQI)
timeFrame: Week 6
Secondary outcomes:
measure: The change in Pittsburgh Sleep Quality Index (PSQI)
timeFrame: Week 3
measure: The change in Pittsburgh Sleep Quality Index (PSQI)
timeFrame: Week 9
measure: Sleep parameter data
timeFrame: From baseline to week 9.
measure: The change in Insomnia Severity Index (ISI)
timeFrame: Week 3
measure: The change in Insomnia Severity Index (ISI)
timeFrame: Week 6
measure: The change in Insomnia Severity Index (ISI)
timeFrame: Week 9
measure: The change in Hospital Anxiety and Depression Scale (HADS)
timeFrame: Week 3
measure: The change in Hospital Anxiety and Depression Scale (HADS)
timeFrame: Week 6
measure: The change in Hospital Anxiety and Depression Scale (HADS)
timeFrame: Week 9
Other outcomes:
Locations:
Study officials:
affiliation: Chinese University of Hong Kong
name: Zhixiu Lin
role: PRINCIPAL_INVESTIGATOR
References: